Sonalasense has filed a notice of an exempt offering of securities to raise $15,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Sonalasense is raising $15,000,000.00 in new funding. Sources indicate that as part of senior management Chief Operating Officer, Mark DeSouza played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Sonalasense
SonALAsense is a clinical-stage company developing ALA sonodynamic therapy (SDT) as a first-in-class, non-invasive drug-device combination for the treatment of recurrent glioblastoma multiforme (rGBM) and other deadly cancers. SDT utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells.
To learn more about Sonalasense, visit http://sonalasense.com/
Contact:
Mark DeSouza, Chief Operating Officer
857-222-4653
https://www.linkedin.com/in/mark-de-souza-196941a/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.